Cont A1

Polypodium and a lipid-soluble fraction from rhizomes of *Polypodium*; and a pharmaceutically acceptable carrier.

Claim 9. (New) The method of Claim 8, wherein said composition comprises 118 mg of said water-soluble fraction and 2 mg of said lipid-soluble fraction.

Claim 10. (New) The method of Claim 8, wherein said adhesion molecule is the alpha chain of integrin β-2, the beta chain of integrin β-2, or both.

Claim 11. (New) The method of Claim 8, wherein said adhesion molecule is CD54.

Claim 12. (New) The method of Claim 8, wherein said adhesion molecule is CD11b, CD6L or a combination thereof.

Claim 13. (New) A method for inhibiting inflammation comprising administering, to a subject in need thereof, a pharmaceutically effective amount of a composition comprising a water-soluble fraction from rhizomes of *Polypodium* and a lipid-soluble fraction from rhizomes of *Polypodium*; and a pharmaceutically acceptable carrier.

Claim 14. (New) The method of Claim 13, wherein said composition comprises 118 mg of said water-soluble fraction and 2 mg of said lipid-soluble fraction.

Claim 15. (New) A method for immuno-modulation comprising administering, to a subject in need thereof, a pharmaceutically effective amount of a composition comprising a water-soluble fraction from rhizomes of *Polypodium* and a lipid-soluble fraction from rhizomes of *Polypodium*; and a pharmaceutically acceptable carrier.

PRELIMINARY AMENDMENT
CHAPTER II filing of PCT/ES00/00026

Claim 16. (New) The method of Claim 15, wherein said composition comprises 118 mg of said water-soluble fraction and 2 mg of said lipid-soluble fraction.

Claim 17. (New) A method for normalization of C4+CD29+CD45RA+ lymphocyte populations comprising administering, to a subject afflicted with a disease wherein said populations are increased, a pharmaceutically effective amount of a composition comprising a water-soluble fraction from rhizomes of *Polypodium* and a lipid-soluble fraction from rhizomes of *Polypodium*; and a pharmaceutically acceptable carrier.

Claim 18. (New) The method of Claim 17, wherein said composition comprises 118 mg of said water-soluble fraction and 2 mg of said lipid-soluble fraction.

Claim 19. (New) A method for treatment of multiple sclerosis comprising administering, to a subject afflicted with multiple sclerosis, a pharmaceutically effective amount of a composition comprising a water-soluble fraction from rhizomes of *Polypodium* and a lipid-soluble fraction from rhizomes of *Polypodium*; and a pharmaceutically acceptable carrier.

Claim 20. (New) The method of Claim 19, wherein said composition comprises 118 mg of said water-soluble fraction and 2 mg of said lipid-soluble fraction. --

REMARKS

The specification has been amended to insert formal matter; Claims 1-7 have been deleted and new Claims 8-20 added in order to remove improper dependency and make the application consistent with U.S. patent practice.